EUCTR2006-006393-14-CZ进行中（未招募）不适用
Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertension Preceded by an Open-Label Pilot Phase - Udenafil tablets vs. placebo in portal hypertension
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent.
- •2. Man or woman between 18 and 70 years of age.
- •3. Compensated liver cirrhosis as proven by clinical findings, laboratory tests, and ultrasound.
- •4. Liver cirrhosis as proven by histology (histology within 5 years prior to Baseline visit) or FibroScan (facultative) or by unequivocal clinical, radiological and laboratory signs.
- •5. Clinically significant portal hypertension defined as HVPG = 12 mm Hg.
- •6. Low risk of bleeding characterized by no or small (< 5 mm in diameter) oesophageal varices proven by endoscopy (previous full variceal banding ligation or obliterative sclerotherapy as primary or secondary prophylaxis for variceal haemorrhage allowed).
- •7. Women of child-bearing potential have to apply double barrier methods of contraception (e.g. oral contraception with condom). The investigator is responsible for determining whether the patient has adequate birth control for study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Child-Pugh C.
- •2. Existing transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt.
- •3. Splenic or portal vein thrombosis by Doppler ultrasonography, magnetic resonance imaging.
- •4. Gastric/duodenal varices with bleeding stigmata (red colour sign or clot) or gastric/duodenal varices with history of bleeding.
- •5. Large oesophageal varices (= 5 mm in diameter).
- •6. Alcoholic hepatitis.
- •7. Hepatic encephalopathy = stage 2.
- •8. Ascites present at Baseline visit.
- •9. Total Bilirubin > 3 mg/dl.
- •10. Bleeding disorder, INR > 2.
- •11. Active peptic ulceration.
- •12. Open-label pilot phase only: Positive Hepatitis B or C serology
- •13. Positive HIV serology
- •14. Anatomical deformation of the penis or penile implants.
- •15. Predisposing priapism, sickle cell anaemia or trait, thrombocythaemia, polycythaemia, prone to venous thrombosis (immobility, surgery of pelvis, abdomen, hip, thrombophilia, history of thrombosis etc.), hyperviscosity syndrome (increased blood viscosity in particular due to polymers typical in multiple myeloma, polycythemia vera, Raynaud’s phenomenon, Waldenström’s macroglobulinemia).
- •16. Known hereditary degenerative retinal disorders, including retinitis pigmentosa.
- •17. Previous episode of NAION.
- •18. Renal failure (GFR < 60 ml/min/1.73 m²).
- •19. QTc prolongation (QTc>440 ms) or treatment with QTc interval-increasing medications.
- •20. Heart failure (NYHA II-IV).
- •21. Angina pectoris.
- •22. History of myocardial infarction, stroke or life-threatening arrhythmia.
- •23. Aortic stenosis.
- •24. Resting hypotension (systolic blood pressure [SBP]/diastolic blood pressure [DBP] < 90/60 mm Hg), uncontrolled hypertension (SBP/DBP > 170/100 mm Hg).
- •25. Symptomatic hypotension (e.g. fainting) following alpha-blocker administration.
- •26. Bacterial infection (positive blood, urine or ascites cultures; or ascites with leucocytes = 500/µl or PMN = 250/µl) within 2 weeks prior to Baseline visit.
- •27. Drugs that may have an effect on splanchnic haemodynamics/portal pressure, e.g. ß-blockers, clonidine, prazosin, nitrates, and any other antihypertensive treatment within 2 weeks prior to Baseline visit (Exception: losartan within 4 weeks prior to Baseline visit).
- •28. Concomitant treatment with ß-blockers, calcium channel blockers, clonidine, prazosin, nitrates, molsidomine, any antihypertensive treatment and any drug which may have an effect on splanchnic haemodynamics/portal pressure.
- •29. Concomitant treatment with vasopressin or somatostatin and their derivatives and analogues.
- •30. Concomitant treatment with platelet aggregation inhibitors, e.g. aspirin, heparin.
- •31. Concomitant treatment with other PDE-5 inhibitors, e.g. sildenafil, tadalafil or vardenafil.
- •32. Treatment with ketoconazole or other CYP3A inhibitors or inducers, consumption of grapefruit juice.
- •33. Active hepatocellular cancer or a history of hepatocellular cancer (to be excluded by ultrasound and tumour markers).
- •34. Active malignancy other than hepatocellular cancer or treatment with anticancer drugs during the last 5 years. Patients with a history of cancer other than hepatocellular cancer and at least five years of uneventful follow up and no signs of recurrence may be eligible.
- •35. Severe co-morbidity substantially reducing life expectancy.
- •36. Known intolerance/hypersensitivity/resistance to study drug or drugs of similar chemical structure or pharmacological profile.
- •37. Doubt about the patient’s cooperation, e.g. because of addiction to alcohol or drugs.
- •38. Existing or intended
研究者
相似试验
进行中（未招募）
不适用
Different doses of Udenafil tablets against portal hypertension for patients with liver cirrhosisEUCTR2006-006393-14-ATDr. Falk Pharma GmbH220
进行中（未招募）
1 期
Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertension Preceded by an Open-Label Pilot Phase - Udenafil tablets vs. placebo in portal hypertensioPortal hypertension, liver cirrhosisMedDRA version: 13.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 13.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006393-14-LTDr. Falk Pharma GmbH220
进行中（未招募）
1 期
Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertension Preceded by an Open-Label Pilot Phase - Udenafil tablets vs. placebo in portal hypertensioPortal hypertension, liver cirrhosisMedDRA version: 13.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 13.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006393-14-DEDr. Falk Pharma GmbH220
进行中（未招募）
1 期
Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF)MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-004157-41-GBGalapagos NV23
进行中（未招募）
1 期
Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF)MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-004157-41-ITGALAPAGOS NV23